Drug Trial Radar · NCT07015697
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
17
Actual
Start
Jul 17, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Jun 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.
Conditions
- Recurrent or Metastatic Solid Tumors
Interventions
Trastuzumab DeruxtecanDrug
Dose Escalation Part: Trastuzumab Deruxtecan will be administered at escalating doses to determine the RDE. Expansion Part: Trastuzumab Deruxtecan will be administered at RDE.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing a Treatment Emergent Adverse Event (TEAE)Time frame: From the start of trial intervention to 21 days after the last dose, up to approximately 9 months
- Area Under Curve (AUC)Time frame: From the start of trial intervention to last dose, up to approximately 9 months
- Number of Participants with Dose limiting toxicities (DLT) During the Dose-Escalation PhaseTime frame: From the start of trial intervention to 21 days after the last dose, up to approximately 9 months
Locations
31 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Newport Beach, California
Research Site
Atlanta, Georgia
Research Site
Las Vegas, Nevada
Research Site
Charlotte, North Carolina
Research Site
Maumee, Ohio
Research Site
Nashville, Tennessee
Research Site
Asa Sul, Brazil
Research Site
Goiás, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Santo André, Brazil
Research Site
São Paulo, Brazil
Research Site Saint
Herblain, France
Research Site
Rennes, France
Research Site
Chiba, Japan
Research Site
Kanagawa, Japan
Research Site
Tokyo, Japan
Research Site
Tokyo, Japan
Research Site
Tokyo, Japan
Research Site
Seongnam-si, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Seoul, South Korea
Research Site
Barcelona, Spain
Research Site
Madrid, Spain
Research Site
Seville, Spain
Research Site
Taichung, Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.